Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 6, pp 1416–1424 | Cite as

Knowledge and pharmacological management of Alzheimer’s disease by managing community pharmacists: a nationwide study

  • Natalie Zerafa
  • Charles ScerriEmail author
Research Article

Abstract

Background Managing community pharmacists can play a leading role in supporting community dwelling individuals with Alzheimer’s disease and their caregivers. Objective The main purpose of this study was to assess knowledge of managing community pharmacists towards Alzheimer’s disease and its pharmacological management. Setting Community pharmacies in the Maltese islands. Method A nationwide survey was conducted with full-time managing community pharmacists in possession of a tertiary education degree in pharmacy studies. The level of knowledge was investigated using the Alzheimer’s Disease Knowledge Scale and the Alzheimer’s Disease Pharmacotherapy Measure. Participants were also asked to rate a number of statements related to disease management. Results Maltese managing community pharmacists (57 % response rate) had inadequate knowledge on risk factors, caregiving issues and pharmacological management of Alzheimer’s disease. Age and number of years working in a community pharmacy setting were found to be negatively correlated with increased knowledge. Conclusion The findings highlight the need of providing training and continued educational support to managing community pharmacists in order to provide quality advice to individuals with dementia and their caregivers in the community.

Keywords

Alzheimer’s disease Dementia Knowledge Malta Maltese islands Managing community pharmacist Pharmacotherapy 

Notes

Acknowledgments

The authors gratefully acknowledge all managing community pharmacists who participated in the study.

Funding

None.

Conflicts of interest

The authors have no conflicts of interests.

References

  1. 1.
    Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet. 1997;349:151–4.CrossRefPubMedGoogle Scholar
  2. 2.
    McGuffey EC. Alzheimer’s disease: an overview for the pharmacist. J Am Pharm Assoc (Wash). 1997;NS37:347–52.CrossRefGoogle Scholar
  3. 3.
    Alzheimer’s Disease International. World Alzheimer Report 2015: The global impact of dementia. 2015. http://www.alz.co.uk/research/world-report-2015. Accessed 10 Mar 2016.
  4. 4.
    Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimer’s Dement. 2008;4:49–60.CrossRefGoogle Scholar
  5. 5.
    Scerri A, Scerri C. Dementia in Malta: new prevalence estimates and projected trends. Malta Med J. 2012;24:21–4.Google Scholar
  6. 6.
    Scerri C. Empowering change: a national strategy for dementia in the Maltese Islands. Valletta: Parliamentary Secretariat for the Rights of Persons with Disability and Active Ageing; 2015.Google Scholar
  7. 7.
    Skelton J. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease. J Am Pharm Assoc. 2008;48:715–21.CrossRefGoogle Scholar
  8. 8.
    Galt KA, Fuji KT, Faber J. Patient safety problem identification and solution sharing among rural community pharmacists. J Am Pharm Assoc. 2013;53:584–94.CrossRefGoogle Scholar
  9. 9.
    Rickles NM, Skelton JB, Davis J, Hopson J. Cognitive memory screening and referral program in community pharmacies in the United States. Int J Clin Pharm. 2014;36:360–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Burns A. The benefits of early diagnosis of dementia. BMJ. 2012;344:e3556.CrossRefPubMedGoogle Scholar
  11. 11.
    Caruana-Pulpan O, Scerri C. Practices in diagnosis, disclosure and pharmacotherapeutic management of dementia by general practitioners—a national survey. Aging Ment Health. 2014;18:179–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;7:73.Google Scholar
  13. 13.
  14. 14.
    Carpenter BD, Balsis S, Otilingam PG, Hanson PK, Gatz M. The Alzheimer’s Disease Knowledge Scale: development and psychometric properties. Gerontologist. 2009;49:236–47.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Polit DF, Beck CT. Essentials of nursing research: appraising evidence for nursing practice. 7th ed. Philadelphia: Lippincott; 2010.Google Scholar
  16. 16.
    Scerri A, Scerri C. Nursing students’ knowledge and attitudes towards dementia—a questionnaire survey. Nurse Educ Today. 2013;33:962–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Nordhus IH, Sivertsen B, Pallesen S. Knowledge about Alzheimer’s disease among Norwegian psychologists. Aging Ment Health. 2012;16:521–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Smyth W, Fielding E, Beattie E, Gardner A, Moyle W, Franklin S, et al. A survey-based study of knowledge of Alzheimer’s disease among health care staff. BMC Geriatr. 2013;13:2.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Koch T, Iliffe S. EVIDEM-ED project. Rapid appraisal of barriers to the diagnosis and management of patients with dementia in primary care: a systemic review. BMC Fam Pract. 2010;11:52.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    de la Torre JC. Basics of Alzheimer’s disease prevention. J Alzheimers Dis. 2010;20:687–8.PubMedGoogle Scholar
  21. 21.
    Herrmann N, Chau SA, Kircanski I, Lanctot KIL. Current and emerging drug treatment options for Alzheimer’s disease: a systemic review. Drugs. 2011;71:2031–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Stella F, Radanovic M, Canineu PR, de Paula VJ, Forlenza OV. Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf. 2015;6:151–65.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    National Institute of Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. 2011. https://www.nice.org.uk/guidance/ta217. Accessed 3 Mar 2016.
  24. 24.
    Mort JR, Gaspar P, Pulscher S, Laird L. Management of demented patients within the community: techniques utilized and the impact of education. Clin Gerontol. 1993;13:23–45.CrossRefGoogle Scholar
  25. 25.
    Banerjee S. The use of antipsychotic medication for people with dementia: time for action. 2009. http://www.rcpsych.ac.uk/pdf/Antipsychotic%20Bannerjee%20Report.pdf. Accessed 5 Mar 2016.
  26. 26.
    Rojas-Fernandez CH, Eng M, Allie ND. Pharmacologic management by clinical pharmacists of behavioural and psychological symptoms of dementia in nursing home residents: results from a pilot study. Pharmacotherapy. 2003;23:217–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Schmidt I, Claesson CB, Westerholm B, Nilsson LG, Svarstad BL. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc. 1998;46:77–82.CrossRefPubMedGoogle Scholar
  28. 28.
    Westbury J, Jackson S, Gee P, Peterson G. An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. Int Psychogeriatr. 2010;22:26–36.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Department of Clinical Pharmacology and TherapeuticsUniversity of MaltaMsidaMalta
  2. 2.Department of Pathology, Faculty of Medicine and SurgeryUniversity of MaltaMsidaMalta

Personalised recommendations